If you suffered losses in DermTech stock, contact DermTech stock loss lawyer Timothy L. Miles about a DermTech class action lawsuit
INTRODUCTION TO THE DERMTECH CLASS ACTION LAWSUIT
The DermTech class action lawsuit seeks to represent purchasers or acquirers of DermTech, Inc. (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). Captioned Bagheri v. DermTech, Inc., No. 23-cv-01885 (S.D. Cal.), the DermTech class action lawsuit charges DermTech and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered losses in DermTech stock and wish to serve as lead plaintiff in the DermTech class action lawsuit, please contact DermTech Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the DermTech class action lawsuit must be filed with the court no later than December 15, 2023.
In this comprehensive guide, we will provide you with all the necessary information regarding the DermTech class action lawsuit, its allegations, the lead plaintiff process, the benefits of serving as a lead plaintiff, and more.
the ALLEGATIONS IN THE DERMTECH CLASS ACTION LAWSUIT
DermTech is a molecular diagnostic company that develops and markets non-invasive genomics test to aid the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The DermTech Melanoma Test (“DMT”) is a commercial test offered to assess pigmented skin lesions for melanoma.
The DermTech class action lawsuit alleges that defendants throughout the Class Period failed to disclose that: (i) DermTech experienced challenges with collections from commercial payors; (ii) as a result, there was a lower average selling price for DermTech’s DMT; and (iii) consequently, DermTech’s revenue growth would be adversely impacted.
The DermTech class action lawsuit further alleges that on August 8, 2022, DermTech announced its second quarter 2022 financial results and revealed that DermTech expected “a lower average selling price (ASP) for [its] DMT,” due to “Medicare billing code edits . . . as well as less favorable collection patterns from commercial payors.” The complaint alleges that on this news DermTech’s stock price fell approximately 34%.
The DermTech class action lawsuit also alleges that on November 3, 2022, DermTech announced its third quarter 2022 financial results, reporting that billable sample volume “sequential growth was flat due to headwinds caused by limited commercial payer coverage.” The DermTech class action lawsuit alleges that DermTech attributed the disappointing growth to “commercial payer collection challenges [have] affect[ed] estimating ASP [average selling price]” and that, as a result, DermTech expected “at least $13 million in assay revenue for the full-year 2022,” which is “below [its] previous guidance range.” The complaint alleges that on this news DermTech’s stock price fell by nearly 45%.
BECOMING THE LEAD PLAINTIFF IN THE DERMTECH CLASS ACTION LAWSUIT
Serving as a Lead Plaintiff in the DermTech class action lawsuit has several advantages and important benefits including:
Thus, there are numerous benefits and other advantages to serving as lead plaintiff in a class action against DermTech if you suffered losses in DermTech stock.
ELIGIBILITY FOR LEAD PLAINTIFF IN THE class action against dermtech
Non-U.S. investors who suffered losses in DermTech stock are also eligible to serve as lead plaintiffs in the class action against DermTech. The lawsuit is not limited to U.S. investors, ensuring that all investors who suffered losses due to DermTech's alleged misconduct can seek legal recourse and potentially recover their losses.
YOU CANNOT BE APPOINTED LEAD PLAINTIFF IN THE class action against DermTech IF YOU PURCHASED SHARES OUTSIDE OF THE CLASS PERIOD
Even if you suffered losses in DermTech stock, if you purchased securities outside of the Class period, you will not be able to participate in the class action against DermTech.
CAN YOU BE APPOINTED LEAD PLAINTIFF IN MULTIPLE LAWSUITS?
Yes, unless you have been a lead plaintiff in more than five securities class actions during any three-year period which is expressly prohibited by the securities laws. Otherwise, if you suffered losses in DermTech stock, you may move to be appointed lead plaintiff in the class action against DermTech.
CLASS PERIOD DETERMINATION IN THE DERMTECH CLASS ACTION LAWSUIT
In the class action against DermTech, the class period refers to the specific timeframe during which the alleged misconduct occurred. For securities fraud class actions, the class period begins when the company makes false or misleading statements or fails to disclose material facts necessary to render other statements not misleading. The class period ends when the truth is revealed to the investing public through a corrective disclosure.
To be included in the DermTech class action lawsuit, you must have suffered losses in DermTech stock by purchasing shares during the class period when the stock's price was allegedly artificially inflated.
HOW A DERMTECH STOCK LOSS LAWYER CAN HELP YOU
If you suffered losses in DermTech stock, it is essential to seek the guidance of a DermTech stock loss lawyer. These lawyers are skilled in navigating the complex laws that govern the securities industry and litigation. They focus on representing individual investors or funds who have been victims of fraud or who have disputes with investment professionals such as the DermTech class action lawsuit.
While regulatory bodies such as FINRA, the SEC, and state securities regulators play a crucial role in protecting investors, they cannot monitor every act of fraud or negligence. By consulting with a securities lawyer, you can ensure that your rights are protected and potentially recover your losses resulting from fraud or stockbroker misconduct.
When selecting a DermTech stock loss lawyer, look for experience, high ethical standards, verifiable credentials, and a trustworthy reputation. Testimonials from previous clients, awards, and recognitions can also help you make an informed decision.
One name that immediately pops-up is nationally known and widely respected Nashville lawyer Timothy L. Miles, who has valuable experience and has received numerous awards, mostly due to his high ethical standards, and hard work ethic, including most recently being named a Top 25 Class action lawyer by the National Trial Lawyers Association, and has maintained an AV rating from Martindale-Hubble since 2014, was named a 2023 Top Rated Litigator and 2023 Top Rated Lawyer by Martindale-Hubble and ALM, and was recently named a 2023 Elite Lawyer of the South by Martindale-Hubble for the fifth year in a row, and was a recipient of Avvo Client’s Choice Award in 2021, in 2022 was featured in the Top 100 Lawyers Magazine and received the Lifetime Achievement Award by Premier Lawyers of America (2019–2021).
This will most likely be the only call you need to make. (855) 846–6529 or [email protected].
BECOMING A MEMBER OF THE CLASS IN THE DERMTECH CLASS ACTION LAWSUIT
If you purchased DermTech shares during the class period and suffered losses, you are likely a member of the class in the DermTech class action lawsuit. As a member of the class, you may participate in the class action against DermTech and potentially share in any settlement or recovery.
CONTACT A DERMTECH STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN DERMTECH STOCK ABOUT A DERMTECH CLASS ACTION LAWSUIT
If you suffered losses in DermTech stock, contact DermTech stock loss lawyer Timothy L. Miles today for a free case evaluation about a DermTech class action lawsuit. Call today and see what a DermTech stock loss lawyer could do for you if you suffered losses in DermTech stock.
DermTech stock loss lawyer Timothy L. Miles
Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, 6Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America's Most Honored Lawyers 2020; Top 1% by America's Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime.
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr., #247
Brentwood, TN 37027
Phone: (855) 846-6529
Email: [email protected]
HOURS OF OPERATION